Beneficial effects of probiotic combination with omega-3 fatty acids in NAFLD: a randomized clinical study
Kobyliak N, Abenavoli L, Falalyeyeva T, Mykhalchyshyn G, Boccuto L, Kononenko L, Kyriienko D, Komisarenko I, Dynnyk O
Minerva medica · 73 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2018-12-01 · Minerva Med · vol. 109 · número 6 · págs. 418–428
- Editorial
- Edizioni Minerva Medica
- Citado
- 108 citas · más que el 99% de estudios similares · 9.9× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 52 trabajos
- Acceso
- De pago
- Áreas de investigación
- Liver Disease Diagnosis and Treatment · Probiotics and Fermented Foods · Gut microbiota and health
- Palabras clave
- non-alcoholic fatty liver disease, probiotics, omega-3 fatty acids, linseed oil, wheat germ oil, type 2 diabetes, gut microbiota, fatty liver index, liver stiffness, shear wave elastography, serum lipids, systemic inflammation, cytokines, gamma-glutamyl transferase
- MeSH
- humans, fatty acids, omega-3, combined modality therapy, double-blind method, probiotics, adult, aged, middle aged, female, male, non-alcoholic fatty liver disease
9 autores
- Nazarii M. Kobyliak🇺🇦Bogomolets National Medical University
- Ludovico Abenavoli🇮🇹Magna Graecia University
- Tetyana M. Falalyeyeva🇺🇦Taras Shevchenko National University of Kyiv
- Galyna Mykhalchyshyn🇺🇦Bogomolets National Medical University
- Luigi Boccuto🇺🇸Greenwood Genetic Center; Clemson University
- Liudmyla Kononenko🇺🇦Bogomolets National Medical University
- Dmytro Kyriienko🇺🇦Bogomolets National Medical University
- Iuliia Komisarenko🇺🇦Bogomolets National Medical University
- Oleh Dynnyk🇺🇦Bogomoletz Institute of Physiology
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
The manipulation of gut microbiota via administration of probiotics has been proposed as a potential strategy for the treatment of non-alcoholic fatty liver disease (NAFLD). Hence, we performed a double-blind single center randomized placebo-controlled trial (RCT) to evaluate the efficacy of coadministration of probiotics with omega-3 vs. placebo in type-2 diabetic patients with NAFLD.
Methods
A total of 48 patients met the criteria for inclusion. They were randomly assigned to receive "Symbiter Omega" combination of probiotic biomass supplemented with flax and wheat germ oil (250 mg of each, concentration of omega-3 fatty acids 1-5%) or placebo for 8-weeks. The primary main outcomes were the change in fatty liver index (FLI) and liver stiffness (LS) measured by Shear Wave Elastography (SWE). Secondary outcomes were the changes in transaminases level, serum lipids and cytokines levels.
Results
In probiotic-omega group, FLI significantly decreased from 83.53±2.60 to 76.26±2.96 (P<0.001) while no significant changes were observed in the placebo group (82.86±2.45 to 81.09±2.84; P=0.156). Changes of LS in both groups were insignificant. Analysis of secondary outcomes showed that the coadministration of probiotics with omega-3 lead to significant reduction of serum gamma-glutamyl transpeptidase, triglycerides, and total cholesterol. Chronic systemic inflammatory markers after intervention decrease significantly only in Symbiter Omega group: IL-1β (P=0.029), TNF-α (P<0.001), IL-8 (P=0.029), IL-6 (P=0.003), and INF-γ (P=0.016).
Conclusions
Coadministration of a live multi-strain probiotic mixture with omega-3 fatty acids once daily for 8 weeks to patients with NAFLD can reduce liver fat, improve serum lipids, metabolic profile, and reduce chronic systemic inflammatory state.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.